Inhibiting DNA methylation improves antitumor immunity in ovarian cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Cancer cells evade immune detection through processes like immune editing and evasion.
• Immunotherapies have transformed cancer treatment but show limited efficacy in most ovarian cancer cases.
• Hypomethylating agents (HMAs) may enhance antitumor immunity, potentially sensitizing ovarian cancer to immunotherapy.

Purpose of the Study:

• To investigate if hypomethylating agent (HMA) treatment can induce antitumor immunity and sensitize ovarian cancer patients to anti-PD-1 immunotherapy.
• To evaluate the combination of guadecitabine (a second-generation HMA) and pembrolizumab (an anti-PD-1 inhibitor) in platinum-resistant ovarian cancer.

Main Methods:

• A Phase II clinical trial was conducted.
• The study included 35 patients with platinum-resistant ovarian cancer.
• Correlative analyses were performed to identify predictive biomarkers.

Main Results:

• The combination of HMA and PD-1 blockade demonstrated a lower-than-expected clinical benefit.
• Correlative analyses provided insights into patient subgroups who might respond better to immunotherapy.
• The study identified potential predictors for immunotherapy response in ovarian cancer.

Conclusions:

• The combination of guadecitabine and pembrolizumab was not highly effective in platinum-resistant ovarian cancer.
• Further research is needed to identify patients most likely to benefit from HMA and immunotherapy combinations.
• Correlative analyses are crucial for optimizing patient selection for ovarian cancer immunotherapy.